
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is experiencing robust growth, evidenced by a remarkable 70% year-over-year subscriber growth in Q4, alongside a diversified service portfolio that reduces concentration risk compared to direct-to-consumer peers focused solely on weight loss. The company's expansion into international markets, coupled with the strategic acquisition of Zava, positions Hims favorably for incremental revenue growth, particularly in its weight-loss segment as it prepares to offer additional drugs currently in development. Furthermore, the anticipated normalization of revenue in conjunction with subscriber growth suggests a favorable outlook as the business transitions through this period of change.
Bears say
Hims & Hers Health is experiencing a significant slowdown in revenue growth, with 4Q:25 results disappointing and a weaker than expected 1Q:26 revenue guidance contributing to a negative outlook. Revenue estimates for F2027E have decreased from $3.7 billion and $535 million in EBITDA to $3.1 billion and $404 million, reflecting a decline in performance expectations. Additionally, the company faces increased legal and regulatory risks, further complicating its financial trajectory.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares